Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
Despite maximizing techniques and patient selection, liver resection and ablation for HCC are still associated with high rates of recurrence. To date, HCC is the only cancer with no proven adjuvant or neoadjuvant therapy used in association to potentially curative treatment. Perioperative combinatio...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/11/2950 |
| _version_ | 1797597775501721600 |
|---|---|
| author | Riccardo Nevola Augusto Delle Femine Valerio Rosato Loreta Anesti Kondili Maria Alfano Davide Mastrocinque Simona Imbriani Pasquale Perillo Domenico Beccia Angela Villani Rachele Ruocco Livio Criscuolo Marco La Montagna Antonio Russo Aldo Marrone Ferdinando Carlo Sasso Raffaele Marfella Luca Rinaldi Nicolino Esposito Giuseppe Barberis Ernesto Claar |
| author_facet | Riccardo Nevola Augusto Delle Femine Valerio Rosato Loreta Anesti Kondili Maria Alfano Davide Mastrocinque Simona Imbriani Pasquale Perillo Domenico Beccia Angela Villani Rachele Ruocco Livio Criscuolo Marco La Montagna Antonio Russo Aldo Marrone Ferdinando Carlo Sasso Raffaele Marfella Luca Rinaldi Nicolino Esposito Giuseppe Barberis Ernesto Claar |
| author_sort | Riccardo Nevola |
| collection | DOAJ |
| description | Despite maximizing techniques and patient selection, liver resection and ablation for HCC are still associated with high rates of recurrence. To date, HCC is the only cancer with no proven adjuvant or neoadjuvant therapy used in association to potentially curative treatment. Perioperative combination treatments are urgently needed to reduce recurrence rates and improve overall survival. Immunotherapy has demonstrated encouraging results in the setting of adjuvant and neoadjuvant treatments for non-hepatic malignancies. Conclusive data are not yet available in the context of liver neoplasms. However, growing evidence suggests that immunotherapy, and in particular immune checkpoint inhibitors, could represent the cornerstone of an epochal change in the treatment of HCC, improving recurrence rates and overall survival through combination treatments. Furthermore, the identification of predictive biomarkers of treatment response could drive the management of HCC into the era of a precision medicine. The purpose of this review is to analyze the state of the art in the setting of adjuvant and neoadjuvant therapies for HCC in association with loco-regional treatments in patients not eligible for liver transplantation and to hypothesize future scenarios. |
| first_indexed | 2024-03-11T03:10:13Z |
| format | Article |
| id | doaj.art-1913420b89f248128a1d151eb544e1f5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T03:10:13Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-1913420b89f248128a1d151eb544e1f52023-11-18T07:38:44ZengMDPI AGCancers2072-66942023-05-011511295010.3390/cancers15112950Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?Riccardo Nevola0Augusto Delle Femine1Valerio Rosato2Loreta Anesti Kondili3Maria Alfano4Davide Mastrocinque5Simona Imbriani6Pasquale Perillo7Domenico Beccia8Angela Villani9Rachele Ruocco10Livio Criscuolo11Marco La Montagna12Antonio Russo13Aldo Marrone14Ferdinando Carlo Sasso15Raffaele Marfella16Luca Rinaldi17Nicolino Esposito18Giuseppe Barberis19Ernesto Claar20Liver Unit, Ospedale Evangelico Betania, 80147 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyLiver Unit, Ospedale Evangelico Betania, 80147 Naples, ItalyCenter for Global Health, Istituto Superiore di Sanità, 00161 Rome, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyLiver Unit, Ospedale Evangelico Betania, 80147 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyLiver Unit, Ospedale Evangelico Betania, 80147 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyLiver Unit, Ospedale Evangelico Betania, 80147 Naples, ItalyMedical Oncology, Ospedale Evangelico Betania, 80147 Naples, ItalyLiver Unit, Ospedale Evangelico Betania, 80147 Naples, ItalyDespite maximizing techniques and patient selection, liver resection and ablation for HCC are still associated with high rates of recurrence. To date, HCC is the only cancer with no proven adjuvant or neoadjuvant therapy used in association to potentially curative treatment. Perioperative combination treatments are urgently needed to reduce recurrence rates and improve overall survival. Immunotherapy has demonstrated encouraging results in the setting of adjuvant and neoadjuvant treatments for non-hepatic malignancies. Conclusive data are not yet available in the context of liver neoplasms. However, growing evidence suggests that immunotherapy, and in particular immune checkpoint inhibitors, could represent the cornerstone of an epochal change in the treatment of HCC, improving recurrence rates and overall survival through combination treatments. Furthermore, the identification of predictive biomarkers of treatment response could drive the management of HCC into the era of a precision medicine. The purpose of this review is to analyze the state of the art in the setting of adjuvant and neoadjuvant therapies for HCC in association with loco-regional treatments in patients not eligible for liver transplantation and to hypothesize future scenarios.https://www.mdpi.com/2072-6694/15/11/2950hepatocellular carcinomarecurrenceadjuvant therapyneoadjuvant therapyimmunotherapyimmune checkpoint inhibitors |
| spellingShingle | Riccardo Nevola Augusto Delle Femine Valerio Rosato Loreta Anesti Kondili Maria Alfano Davide Mastrocinque Simona Imbriani Pasquale Perillo Domenico Beccia Angela Villani Rachele Ruocco Livio Criscuolo Marco La Montagna Antonio Russo Aldo Marrone Ferdinando Carlo Sasso Raffaele Marfella Luca Rinaldi Nicolino Esposito Giuseppe Barberis Ernesto Claar Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? Cancers hepatocellular carcinoma recurrence adjuvant therapy neoadjuvant therapy immunotherapy immune checkpoint inhibitors |
| title | Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? |
| title_full | Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? |
| title_fullStr | Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? |
| title_full_unstemmed | Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? |
| title_short | Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? |
| title_sort | neoadjuvant and adjuvant systemic therapies in loco regional treatments for hepatocellular carcinoma are we at the dawn of a new era |
| topic | hepatocellular carcinoma recurrence adjuvant therapy neoadjuvant therapy immunotherapy immune checkpoint inhibitors |
| url | https://www.mdpi.com/2072-6694/15/11/2950 |
| work_keys_str_mv | AT riccardonevola neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT augustodellefemine neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT valeriorosato neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT loretaanestikondili neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT mariaalfano neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT davidemastrocinque neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT simonaimbriani neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT pasqualeperillo neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT domenicobeccia neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT angelavillani neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT racheleruocco neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT liviocriscuolo neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT marcolamontagna neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT antoniorusso neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT aldomarrone neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT ferdinandocarlosasso neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT raffaelemarfella neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT lucarinaldi neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT nicolinoesposito neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT giuseppebarberis neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera AT ernestoclaar neoadjuvantandadjuvantsystemictherapiesinlocoregionaltreatmentsforhepatocellularcarcinomaareweatthedawnofanewera |